Ahren - Innovation Capital
We imagine

and create

the unimaginable

We wrote in April to summarise positive developments in therapeutics, testing, and other efforts attempting to tackle Covid-19. Today is the first of a three part blog series to provide an update on what we have learnt since then... http://www.ahreninnovationcapital.com/covid-19-update-part-1-3-learnt-last-six-weeks/

"We must seize this opportunity. We owe it to the wisdom and innovation of our forebears, on whose shoulders we stand... And we owe it to the generations to come, whose fate may depend on the actions we take." Lord Martin Rees, Ahren Science Partner

This pandemic was entirely predictable. Why were we so poorly prepared?

Britain's flawed approach towards existential risk needs to change radically in the wake of this crisis

www.telegraph.co.uk

.@MCT_AACR has published our research paper describing the preclinical profile of our Bicycle® Toxin Conjugate BT5528, which is shown to have unique properties thought to enable a wider therapeutic window than that of ADCs. Read more in today’s PR: http://bit.ly/2LmMmVQ

Load More...
We imagine

and create

the unimaginable

We wrote in April to summarise positive developments in therapeutics, testing, and other efforts attempting to tackle Covid-19. Today is the first of a three part blog series to provide an update on what we have learnt since then... http://www.ahreninnovationcapital.com/covid-19-update-part-1-3-learnt-last-six-weeks/

"We must seize this opportunity. We owe it to the wisdom and innovation of our forebears, on whose shoulders we stand... And we owe it to the generations to come, whose fate may depend on the actions we take." Lord Martin Rees, Ahren Science Partner

This pandemic was entirely predictable. Why were we so poorly prepared?

Britain's flawed approach towards existential risk needs to change radically in the wake of this crisis

www.telegraph.co.uk

.@MCT_AACR has published our research paper describing the preclinical profile of our Bicycle® Toxin Conjugate BT5528, which is shown to have unique properties thought to enable a wider therapeutic window than that of ADCs. Read more in today’s PR: http://bit.ly/2LmMmVQ

Load More...